Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy

Immuron Limited has engaged Pullan Consulting to secure a strategic partnership for IMM-529, its investigational polyclonal antibody treatment for Clostridioides difficile infection (CDI). The company has FDA approval for the IND application and is preparing for Phase 2 clinical trials in Australia. Based on market assessments, IMM-529 could generate projected annual revenues of US$400M if efficacious, with potential partnership deals ranging from US$1-50M upfront plus significant milestone payments and royalties.